STAT+ Conversation: Which biotech venture capital funds performed best during the pandemic?

Editor’s note: A recording of the conversation is embedded below.

Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma, and health tech leaders. This week, STAT senior medicine writer and editorial director of events Matthew Herper and STAT general assignment reporter Kate Sheridan sit down to discuss the second edition of her report “Ranking biotech’s top venture capital firms.”  They will explore which venture capital funds performed best during the pandemic, and of course be taking your questions live.

Featured speakers

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In